Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2000 Sep;55(9):780–784. doi: 10.1136/thorax.55.9.780

Salmeterol in paediatric asthma

C Byrnes 1, S Shrewsbury 1, P Barnes 1, A Bush 1
PMCID: PMC1745864  PMID: 10950898

Abstract

BACKGROUND—The addition of long acting inhaled β2 agonists is recommended at step 3 of the British guidelines on asthma management but a recent study suggested no additional benefit in children with asthma.
METHODS—The aim of this study was to compare, in a double blind, three way, crossover study, the effects of the addition of salmeterol 50 µg bd, salmeterol 100 µg bd, and salbutamol 200 µg qds in asthmatic children who were symptomatic despite treatment with inhaled corticosteroids in a dose of at least 400 µg/day over a one month period. Symptom scores, morning and evening peak expiratory flow (PEF) rates, use of rescue medication, spirometric indices, and histamine challenge were measured.
RESULTS—Forty five children aged 5-14 years were enrolled. All three treatments improved asthma control, morning and evening PEF rates, and spirometric indices with no change in bronchial hyperreactivity. Mean morning PEF was significantly better during the salmeterol treatment periods than with salbutamol treatment (p<0.05). The analysis of mean morning PEF gave an estimated treatment difference of 9.6 l/min for salmeterol 50 µg bd versus salbutamol 200 µg qds (95% confidence interval (CI) 2.1 to 17.1), and an estimated treatment difference of 13.8 l/min for salmeterol 100 µg bd versus salbutamol 200 µg qds (95% CI 6.0 to 21.5). There were no significant differences between the two doses of salmeterol and all treatments were well tolerated.
CONCLUSIONS—In this population of moderate to severe asthmatic children on inhaled corticosteroids, salmeterol in a dose of either 50 µg bd or 100 µg bd is significantly more effective at increasing the morning PEF rate over a one month period than salbutamol 200 µg qds. The data provided no significant evidence of a difference in efficacy between the two doses of salmeterol, 50 µg and 100 µg. A trial of salmeterol 100 µg bd may be worth considering in those still symptomatic on the lower dose.



Full Text

The Full Text of this article is available as a PDF (156.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byrnes C. A., Dinarevic S., Shinebourne E. A., Barnes P. J., Bush A. Exhaled nitric oxide measurements in normal and asthmatic children. Pediatr Pulmonol. 1997 Nov;24(5):312–318. doi: 10.1002/(sici)1099-0496(199711)24:5<312::aid-ppul2>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Cai Y., Carty K., Henry R. L., Gibson P. G. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children. Eur Respir J. 1998 Apr;11(4):848–853. doi: 10.1183/09031936.98.11040848. [DOI] [PubMed] [Google Scholar]
  3. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  4. Haley K. J., Drazen J. M. Inflammation and airway function in asthma: what you see is not necessarily what you get. Am J Respir Crit Care Med. 1998 Jan;157(1):1–3. doi: 10.1164/ajrccm.157.1.ed-19. [DOI] [PubMed] [Google Scholar]
  5. Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
  6. Lenney W., Pedersen S., Boner A. L., Ebbutt A., Jenkins M. M. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr. 1995 Dec;154(12):983–990. doi: 10.1007/BF01958642. [DOI] [PubMed] [Google Scholar]
  7. Meijer G. G., Postma D. S., Mulder P. G., van Aalderen W. M. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1887–1892. doi: 10.1164/ajrccm.152.6.8520751. [DOI] [PubMed] [Google Scholar]
  8. Nelson B. V., Sears S., Woods J., Ling C. Y., Hunt J., Clapper L. M., Gaston B. Expired nitric oxide as a marker for childhood asthma. J Pediatr. 1997 Mar;130(3):423–427. doi: 10.1016/s0022-3476(97)70204-x. [DOI] [PubMed] [Google Scholar]
  9. Nelson J. A., Strauss L., Skowronski M., Ciufo R., Novak R., McFadden E. R., Jr Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998 Jul 16;339(3):141–146. doi: 10.1056/NEJM199807163390301. [DOI] [PubMed] [Google Scholar]
  10. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  11. Primhak R. A., Smith C. M., Yong S. C., Wach R., Kurian M., Brown R., Efthimiou J. The bronchoprotective effect of inhaled salmeterol in preschool children: a dose-ranging study. Eur Respir J. 1999 Jan;13(1):78–81. doi: 10.1183/09031936.99.13107899. [DOI] [PubMed] [Google Scholar]
  12. Russell G., Williams D. A., Weller P., Price J. F. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995 Nov;75(5):423–428. [PubMed] [Google Scholar]
  13. Simons F. E. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med. 1997 Dec 4;337(23):1659–1665. doi: 10.1056/NEJM199712043372304. [DOI] [PubMed] [Google Scholar]
  14. Sont J. K., Willems L. N., Bel E. H., van Krieken J. H., Vandenbroucke J. P., Sterk P. J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1043–1051. doi: 10.1164/ajrccm.159.4.9806052. [DOI] [PubMed] [Google Scholar]
  15. Verberne A. A., Frost C., Duiverman E. J., Grol M. H., Kerrebijn K. F. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med. 1998 Jul;158(1):213–219. doi: 10.1164/ajrccm.158.1.9706048. [DOI] [PubMed] [Google Scholar]
  16. Verberne A. A., Frost C., Roorda R. J., van der Laag H., Kerrebijn K. F. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):688–695. doi: 10.1164/ajrccm.156.3.9611067. [DOI] [PubMed] [Google Scholar]
  17. Verberne A. A., Hop W. C., Creyghton F. B., van Rooij R. W., van den Berg M., de Jongste J. C., Kerrebijn K. F. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immunol. 1996 Apr;97(4):938–946. doi: 10.1016/s0091-6749(96)80068-6. [DOI] [PubMed] [Google Scholar]
  18. Weinstein S., Chervinsky P., Pollard S. J., Bronsky E. A., Nathan R. A., Prenner B., Howland W. C., 3rd, Stahl E., Liddle R. A one-week dose-ranging study of inhaled salmeterol in children with asthma. J Asthma. 1997;34(1):43–52. doi: 10.3109/02770909709071202. [DOI] [PubMed] [Google Scholar]
  19. Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]
  20. de Benedictis F. M., Tuteri G., Pazzelli P., Niccoli A., Mezzetti D., Vaccaro R. Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses. Eur Respir J. 1996 Oct;9(10):2099–2103. doi: 10.1183/09031936.96.09102099. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES